Cargando…
Adaptively evolved human oral actinomyces‐sourced defensins show therapeutic potential
The development of eukaryote‐derived antimicrobial peptides as systemically administered drugs has proven a challenging task. Here, we report the first human oral actinomyces‐sourced defensin—actinomycesin—that shows promise for systemic therapy. Actinomycesin and its homologs are only present in ac...
Autores principales: | Zhu, Shunyi, Gao, Bin, Umetsu, Yoshitaka, Peigneur, Steve, Li, Ping, Ohki, Shinya, Tytgat, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819291/ https://www.ncbi.nlm.nih.gov/pubmed/34927385 http://dx.doi.org/10.15252/emmm.202114499 |
Ejemplares similares
-
The Fungal Defensin Family Enlarged
por: Wu, Jiajia, et al.
Publicado: (2014) -
Craniofacial Actinomyces osteomyelitis evolving from sinusitis
por: Shen, Joseph Y., et al.
Publicado: (2017) -
The antifungal plant defensin AtPDF2.3 from Arabidopsis thaliana blocks potassium channels
por: Vriens, Kim, et al.
Publicado: (2016) -
Actinomyces Produces Defensin-Like Bacteriocins (Actifensins) with a Highly Degenerate Structure and Broad Antimicrobial Activity
por: Sugrue, Ivan, et al.
Publicado: (2020) -
A Fungal Defensin Targets the SARS−CoV−2 Spike Receptor−Binding Domain
por: Gao, Bin, et al.
Publicado: (2021)